Aim
To evaluates the effectiveness and safety of the first generation, NS3/4A protease inhibitors (PIs) in clinical practice against chronic C virus, especially in patients with advanced fibrosis.Methods
Prospective study and non-experimental analysis of a multicentre cohort of 38 Sp...